Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2020

View Archived Issues

MMA induces epithelial-to-mesenchymal transition

CAR T cells for inhibition

First healthy volunteers enrolled in phase I study of GRAd-COV2 COVID-19 vaccine candidate

Trevena initiates proof-of-concept study of TRV-027 in patients with COVID-19

BIIB-091: a potent, highly selective BTK inhibitor for the treatment of multiple sclerosis

GB-1211, first orally available galectin-3 inhibitor as potential treatment for NASH

Nicotinamide riboside suppresses inflammatory activation of PBMC in heart failure

Kyorin Pharmaceutical presents new 15-PGDH inhibitors

New DNA polymerase theta inhibitors discovered at Ideaya Biosciences

Foghorn Therapeutics patents PROTACs targeting BRD9

Canwell Biotech identifies new TLR7/8 agonists

New sphingomyelin phosphodiesterase 3 inhibitors discovered at Johns Hopkins University

Antifungal immunity helps out antibacterial vaccine

FDA clears IND for phase II study of RGX-314 for diabetic retinopathy

Immunogenicity of an saRNA lipid NP vaccine candidate encoding the SARS-CoV-2 S protein in mice

Topline data presented from phase II ELEKTRA study of soticlestat

AtlasMedx initiates phase I/II study of AMXI-5001 in advanced malignancies

Positive topline data from phase IIa trial of IMVT-1401 in myasthenia gravis

Mereo BioPharma initiates phase Ib/II study of alvelestat in COVID-19 respiratory disease

Phase III ASCEMBL study of asciminib in CML meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...